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A B S T R A C T
The Teladorsagia circumcincta P-glycoprotein-9 (Tci-pgp-9) gene has previously been implicated in multiple-an-
thelmintic resistance in this parasite. Here we further characterise genetic diversity in Tci-pgp-9 and its possible
role in ivermectin (IVM) and multi-drug resistance using two UK ﬁeld isolates of T. circumcincta, one susceptible
to anthelmintics (MTci2) and the other resistant to most available anthelmintics including IVM (MTci5). A
comparison of full-length Tci-pgp-9 cDNA transcripts from the MTci2 and MTci5 isolates (∼3.8 kb in both cases)
indicated that they shared 95.6% and 99.5% identity at the nucleotide and amino acid levels, respectively. Nine
non-synonymous SNPs were found in the MTci5 sequences relative to their MTci2 counterparts. Twelve genomic
sequence variants of the ﬁrst internucleotide binding domain of Tci-pgp-9 were identiﬁed and up to 10 of these
were present in some individual worms, strongly supporting previous evidence that ampliﬁcation of this gene
has occurred in T. circumcincta. On average, fewer distinct sequence variants of Tci-pgp-9 were present in in-
dividual worms of the MTci5 isolate than in those of the MTci2 isolate. A further reduction in the number of
sequence variants was observed in individuals derived from an IVM-treated sub-population of MTci5. These
ﬁndings suggest that Tci-pgp-9 was under purifying selection in the face of IVM treatment in T. circumcincta, with
some sequence variants being selected against.
1. Introduction
The control of parasitic nematodes of ruminants, such as
Teladorsagia circumcincta, currently relies heavily on the use of anthel-
mintic drugs, and this has led to widespread selection for drug re-
sistance. Anthelmintic resistance in T. circumcincta has been docu-
mented in most countries where this parasite occurs (Kaplan, 2004) and
it has been reported in UK ﬁeld populations against three of the ﬁve
major classes of anthelmintics. Resistance to single and multiple classes
of anthelmintic has frequently been diagnosed in populations of this
species, with ‘triple-resistance’ (i.e. resistant to benzimidazoles (BZs),
imidothiazoles and macrocyclic lactones (MLs)) being reported in T.
circumcincta isolates from sheep in Europe more than a decade ago
(Sargison et al., 2001). Although as yet there have been no reported
ﬁeld cases in the UK of resistance to the amino-acetonitrile derivative
class of anthelmintics, which includes Monepantel, monepantel-re-
sistance has been observed in T. circumcincta under experimental con-
ditions (Bartley et al., 2015). Disturbingly, monepantel-resistance has
been reported in ﬁeld populations of T. circumcincta (and Trichostronglus
colubriformis) from sheep and goats in New Zealand (Leathwick et al.,
2013; Scott et al., 2013) and in Haemonchus contortus in sheep in Aus-
tralia (Sales and Love, 2016) and in the Netherlands (Van den Brom
et al., 2015).
Anthelmintic resistance in most cases is accepted as a pre-adaptive
phenomenon (Jackson and Coop, 2000) in which the genes responsible
for resistance already exist at a low frequency within a population but
become dominant under drug selection. Anthelmintic resistance has
been attributed to several genetic factors including qualitative and/or
quantitative changes in putative drug targets (e.g. glutamate-gated
chloride channels and β-tubulin), and members of the adenosine tri-
phosphate (ATP)-binding cassette (ABC)-transporter superfamily (P-
glycoproteins (Pgps), multi-drug resistant proteins and half-transpor-
ters) have also been implicated (Xu et al., 1998; Prichard and Roulet,
2007; James and Davey, 2009; Dupuy et al., 2010). Pgps have been
implicated in the molecular basis of IVM-resistance in H. contortus (Xu
et al., 1998; Molento and Prichard, 2001), and polymorphisms in cer-
tain alleles have the potential to improve drug eﬄux from the cell,
thereby changing the drug distribution within the parasite's tissues and
preventing anthelmintics reaching their site of action (Wolstenholme
et al., 2004; Prichard and Roulet, 2007). Studies in which IVM or
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Fig. 1. Amino Acid Sequence of Tci-pgp-9
Amino acid sequences from the UK isolates MTci2 and MTci5, aligned with sequence information derived from two near-isogenic strains of T. circumcincta from NZ. The ﬁrst of the NZ
strains (NZ-S) was known to be susceptible to all available anthelmintics while the second (NZ-R), which shared a largely common genetic background, was multiple-anthelmintic
resistant. Sequence motifs are underlined and annotated above the sequence. The positions of inter-nucleotide binding domains A and B (IBDA and IBDB) are underlined and annotated
below the sequences. Highlighted in yellow are six residue substitutions identiﬁed in the UK isolates (numbered 1–6), and four previously identiﬁed residue substitutions in NZ isogenic
strains (annotated A-D).
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moxidectin (MOX) were co-administered with Pgp-inhibitors (such as
verapamil) have shown increased eﬃcacy of these drugs against MOX-
resistant H. contortus (Xu et al., 1998; Molento et al., 2004; Bartley
et al., 2009). Functional recombinant expression of Cylicocyclus elon-
gatus pgp-9 in a Saccharomyces cerevisiae strain that was deﬁcient in
endogenous ABC-transported demonstrated that MLs are substrates for
pgp-9 in this equine parasite (Kaschny et al., 2015). Moreover, recent
studies have linked polymorphisms in Pgps with a multi-drug-resistant
phenotype in T. circumcincta (Bisset, 2007; Dicker et al., 2011a, 2011b),
H. contortus (Blackhall et al., 1998; Williamson et al., 2011), Cooperia
oncophora (Demeler et al., 2013), Parascaris equorum (Janssen et al.,
2013) and Onchocerca volvulus (Bourguinat et al., 2008). Increased ex-
pression of Pgp genes has also been associated with IVM resistance in T.
circumcincta (Dicker et al., 2011b; Raza et al., 2016; Choi et al., 2017)
H. contortus (Xu et al., 1998), C. oncophora (Areskog et al., 2013; De
Graef et al., 2013) and C. elegans (James and Davey, 2009).
One speciﬁc Pgp gene, Tci-pgp-9, has been associated with multi-
drug resistant phenotypes in two independent studies which demon-
strated an increase in expression and polymorphisms in Tci-pgp-9 from
multiple-anthelmintic resistant T. circumcincta (Bisset, 2007; Dicker,
2010). Bisset (2007) and subsequently Choi et al. (2017) have reported
gene ampliﬁcation, alternative splicing and four non-synonymous,
exonic SNPs in Tci-pgp-9 when comparing a multiple-anthelmintic re-
sistant strain with its anthelmintic-susceptible “near-isogenic” sister
strain in New Zealand (NZ). Using ﬁeld isolates from the UK, Dicker
(2010) showed that there was a higher level of constitutive expression
of Tci-pgp-9 in the anthelmintic resistant isolate (MTci5) in all life-cycle
stages, relative to an unrelated susceptible isolate (MTci2). In a sub-
sequent study conducted on an IVM-exposed population of MTci5,
evidence for inducible Tci-pgp-9 expression was also obtained (Dicker
et al., 2011b). Signiﬁcantly higher levels of transcription of pgp-9.1 and
pgp-9.2 have similarly been shown in comparisons of anthelmintic
susceptible and resistant isolates of H. contortus following in vitro ex-
posure to IVM and LEV (Raza et al., 2016).
MTci2 FFGMSAERLTMRLRSK IFKNVMRMDATYFDMPRHSPGKITTRLATDAPNVKSALDYRFGSVFSSVVSVCS  840
MTci5 ......................................................................  840
NZ- S  ......................................................................  840
NZ- R  ........... ...........................................................  840
MTci2 GVGIALYFGWQMAILT IAIFPLAAVGQAIQMKFMSGRATADAKEMENSGKVAMEAIENIRTVQALTLEHR  910
MTci5 ......................................................................  910
NZ- S  ......................................................................  910
NZ- R  ........... ...........................................................  910
MTci2 LHAQFCQHLDAPHKTS RRKAIIQGISYGFASSIFYFLYASCFRFGLWLIVNGTLQPMNVLRVLFAISFTA  980
MTci5 ......................................................................  980
NZ- S  ......................................................................  980
NZ- R  ........... ...........................................................  980
( C)              
MTci2 GSMGFASS YFPEYIKATFAAGLIFHMLEEEPRIDGMTSNGKKPKITGAVKLNKVYFKYPERP NVPILQGM 1050
MTci5 .............................................................. N....... 1050
NZ- S  .............................................................. N....... 1050
NZ- R  ... ........................................................... D....... 1050
Walker A ( D)        Q- Loop/Lid
MTci2 DVDVKPGETLALV GPSGCGKS TVISLLERLYDALDGSVEVDGNDLR QVNPTHLRAH IALVSQEPIL FDRS 1120
MTci5 .............................................. Q....................... 1120
NZ- S  .............................................. E ....................... 1120
NZ- R  .............................................. Q....................... 1120
I BDB  
( 6 )                                     Signature
MTci2 IRDNILYGLP QGSVSDAQVHEVAQR ANIHSFIIGLPDGYNTRAGEKGAQ LSGGQKQRIAIARAL VRNPK I 1190
MTci5 .......... P ........................................................... 1190
NZ- S  .......... P ........................................................... 1190
NZ- R  .......... P ......... .................................................. 1190

Walker B D - Loop                 Switch                                                  
MTci2 LLLDEATSALDTES EKVVQEALDKASEGRT CIVVAHRLS TVVNANCIMVVKGGKVVEKGTHNELMQAKGA 1260
MTci5 ...................................................................... 1260
NZ- S  ................................................................... ... 1260
NZ- R  ...................................................................... 1260
 
MTci2 YWALTQKQILAKE - 1273
MTci5 ............. - 1273
NZ- S  ............. - 1273
NZ- R  ............. - 1273
Fig. 1. (continued)
F. Turnbull et al. IJP: Drugs and Drug Resistance 8 (2018) 70–80
72
The aim of the present study was to further characterise Tci-pgp-9
and its putative role in IVM resistance in T. circumcincta. Speciﬁcally,
we wished to sequence similar regions of the gene in susceptible and
resistant isolates from the UK to determine whether there was an as-
sociation of drug resistance with any speciﬁc sequence variants, and to
develop a genotyping assay and determine the frequencies of the dif-
ferent sequence variants in susceptible and resistant isolates, and in the
resistant isolate after further selection with IVM.
2. Materials & methods
2.1. Parasite isolates
Two ﬁeld isolates of T. circumcincta from the UK were used: MTci2,
an isolate with veriﬁed susceptibility to IVM, levamisole (LEV) and BZs
(Skuce et al., 2010; D. Bartley, Pers. Comm.), and MTci5, a multiple-
anthelmintic resistance isolate from a Scottish lowland sheep farm
which was ﬁrst described by Sargison et al. (2001) and has since been
shown to be resistant to BZs, LEV and IVM (Bartley et al., 2004, 2005).
A separate population of MTci5, representing progeny from adult sur-
vivors of IVM treatment, was generated for the current study by treating
an experimentally infected donor lamb with IVM at the manufacturer's
recommended dose rate (0.2 mg/kg). Faecal samples were collected
from day-21 post-treatment, eggs were recovered and cultured to third-
stage larvae (L3). This IVM-screened population is, henceforth, referred
to as MTci5 Post-Treatment (MTci5PT).
In addition, sequences from two near-isogenic lines of T. cir-
cumcincta generated in New Zealand, one susceptible to the available
anthelmintic classes and the other resistant to multiple-anthelmintic
classes (Bisset, 2007; Choi et al., 2017), were used in the present study
for comparative purposes.
2.2. Generation of full-length Tci-pgp-9 cDNA sequence from UK isolates
The primers used for ﬁrst strand cDNA synthesis of Tci-pgp-9, and
subsequent PCR ampliﬁcation, are listed in the Supplementary Table
S1. RNA for this work was extracted from pools of L3 from the re-
spective MTci2 and MTci5 isolates and approximately 100 ng were re-
verse transcribed to cDNA using rapid ampliﬁcation of cDNA ends
(RACE) to generate the sequences of the 5′ and 3′ untranslated regions
(UTR). A cDNA fragment at the 5′ end of Tci-pgp-9 was generated using
the antisense primer, Tci-pgp-9_A1, and the sense primer Tci-pgp-9_5′_F1,
which incorporated part of the spliced leader-1 sequence (Krause and
Hirsh, 1987). To amplify the 3′ region, a 3′ RACE approach was used
replacing the Oligo(dT)20 primer with the Tci-pgp-9_3′RACE_dT primer
in the SuperScript™ III First-Strand Synthesis System for RT-PCR (In-
vitrogen) kit, following the manufacturer's protocol, which provided a
binding site for the adapter-speciﬁc nested primer, Tci-pgp-9_3′RACE.
The full-length Tci-pgp-9 transcript was ampliﬁed using Platinum®
Taq DNA Polymerase High Fidelity (Invitrogen) in a ﬁnal volume of
50 μl (High Fidelity PCR Buﬀer, 0.2 μM of dNTP mix, 2mM MgSO4,
1 μM of each primer, 1 unit of Platinum® Taq High Fidelity, 1 μl tem-
plate cDNA), under the following conditions: initial denaturing at 94 °C
for 2min followed by 35 three-step cycles of 94 °C for 30 s, 55 °C for
30 s, 68 °C for 4min with a ﬁnal extension step of 68 °C for 5min. The
primer pair Tci-pgp-9_5′_F2 and Tci-pgp-9_R2 was used for the MTci2
isolate, and Tci-pgp-9_5′_F1 and Tci-pgp-9_R1 was used for the MTci5
isolate. Amplicons of the expected size (∼3.8 kb) were ligated into
pGEM®-T Easy Vector (Promega) and transformed into chemically
competent JM109 E. coli (Promega), following the manufacturer's
protocols. Three clones derived from each UK isolate were sequenced in
both sense and antisense directions.
2.3. Sequence variant-speciﬁc PCR
Crude gDNA lysates were generated from individual L3 lysed in
10 μl of a 3% solution of recombinant PCR grade proteinase K (Roche)
in PCRDirect lysis reagent (Tail) (Viagen Biotech). Lysis was achieved
by incubating at 55 °C for 16 h, followed by incubation at 90 °C for 1 h
to denature the proteinase K.
Fragments representing the ﬁrst (“N-terminal”) internucleotide
binding domain of the Tci-pgp-9 gene (Tci-pgp-9-IBDA) were ampliﬁed
from gDNA lysates prepared from 84 individual L3 randomly selected
from each of the MTci2, MTci5, and MTci5PT isolates. A nested PCR
was used, with the initial reaction using the primer pair Tci-pgp-
9_IBDAGF3B and Tci-pgp-9_IBDAGR2 (Table S1). The use of degenerate
primers increased the likelihood of amplifying all potential sequence
variants present in these isolates. End-point PCR was performed with
each 10 μl reaction containing Taq buﬀer, 2.5 mM MgCl2, dNTP mix
(4 μM each), 0.5 units of Platinum® Taq (all Invitrogen), 1 μM each
primer and 1 μl template gDNA (crude lysate). Reactions were carried
out using the following thermocycling program: 94 °C for 8min, fol-
lowed by 35 three-step cycles of 94 °C for 10 s, 50 °C for 20 s and 68 °C
for 40 s, followed by a ﬁnal elongation step of 68 °C for 7min.
A similar Platinum® Taq nested-PCR reaction was undertaken using
1 μl of a 50-fold dilution of the primary reactions as template with the
primer pair, Tci-pgp-9_IBDAGF4 and Tci-pgp-9_IBDAGR3. Successful PCR
ampliﬁcation and evidence of amplicon length variants present in each
T. circumcincta larva were assessed using a QIAxcel Advance System
(QIAgen) using the QIAxcel Screening Kit (QIAgen), and analysed using
Fig. 2. Secondary Nested PCR Products from MTci2 (individuals
1–12)
Virtual gel output from the QIAxcel Advanced System showing
the secondary nested-PCR amplicons generated using primer pair
Tci-pgp-9_IBDAGF4 and Tci-pgp-9_IBDAGR3 from a selection of
individuals of the MTci5 strain. The alignment markers, 15 bp
and 1 kb are shown in each lane along with PCR products of
diﬀering sizes, ranging from ∼500 to 800 bp. The QX DNA Size
Marker 50–800 bp (v2.0) is highlighted in lane H12.
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the QIAxcel ScreenGel 1.0.2 software (QIAgen). Tci-pgp-9-IBDA PCR
products from 37 individuals (10 from MTci2, 11 from MTci5, and 16
from MTci5PT) were selected for sequencing to account for each of the
diﬀerent sized amplicons observed. These were ligated into pCR® 4-
TOPO® Vector (Invitrogen), transfected into One Shot® TOP10
Electrocomp™ Cells (Invitrogen), plasmids puriﬁed and the amplicon
inserts sequenced.
The DNA sequences generated from the initial Tci-pgp-9-IBDA PCR
products were aligned with 9 sequence variants (numbered NZv1-3,
NZv5-10) that had previously been identiﬁed from NZ isolates of T.
circumcincta (Bisset, 2007). Sequence variant-speciﬁc primers
(Supplementary Table S1) were designed to target polymorphic regions
within the introns of Tci-pgp-9-IBDA and were used to diﬀerentiate
among variants (Fig. 3). Each sequence variant-speciﬁc antisense
primer was paired with a degenerate (‘non variant-speciﬁc’) sense
primer, Tci-pgp-9_IBDAGF5, located near the 5′ end of the Tci-pgp-9-
IBDA fragment initially ampliﬁed with the primer pair Tci-pgp-9_IB-
DAGF3B and Tci-pgp-9_IBDAGR2. A touchdown and nested PCR strategy
was adopted for the sequence variant-speciﬁc PCR reactions where the
template used was a 50-fold dilution of the PCR products ampliﬁed
using the primers, Tci-pgp-9_IBDAGF3B and Tci-pgp-9_IBDAGR2. The
touchdown PCR thermocycling conditions were: 94 °C for 8min, then
12 three-step cycles with decreasing annealing temperature by 0.5 °C
per cycle, starting at 94 °C for 10 s, at 62 °C for 20 s and 68 °C for 30 s,
Fig. 3. Sequence Variants Within the Tci-pgp-9-IBDA Domain of UK strains MTci2 and MTci5
Clustal Omega multiple alignment of partial gDNA sequences of Tci-pgp-9 sequence variants showing introns (shaded) and predicted amino acid translation (underlined). The locations of
sequence variant-speciﬁc primers (boxed) designed to distinguish between sequence variants are shown and the primers used are listed in Table S1.
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each cycle; this was followed by 24 three-step cycles of 94 °C for 10 s,
56 °C for 20 s and 68 °C for 30 s with a ﬁnal extension step of 68 °C for
5min. PCR products were analysed using the QIAxcel Advanced System
and the QIAxcel DNA Screening Kit (QIAgen).
2.4. Statistical analyses
Sequence data were assembled and analysed using SeqMan Pro™
software from DNASTAR® Lasergene® v15 with default parameters.
Molecular phylogenetic analyses were conducted using Molecular
Evolutionary Genetics Analysis (MEGA) v7.0.26 software (Kumar et al.,
2016) to select the best ﬁt substitution model. The Maximum Like-
lihood method based on the Kimura 2-parameter model (Kimura, 1980)
was used to construct a bootstrap consensus tree inferred from 2000
replicates (Felsenstein, 1985) to show the relationships between the
sequence variants of Tci-pgp-9-IBDA, found in the UK and NZ strains of
T. circumcincta, respectively. A discrete Gamma distribution was used to
model evolutionary rate diﬀerences among sites (5 categories (+G,
parameter = 0.6377)). Sequence variants identiﬁed from the UK strains
were numbered according to their relationships with sequence variants
identiﬁed from the NZ resistant and susceptible isolates (Bisset, 2007).
Those that diﬀered by≥ 10% were recorded as new variants and
numbered accordingly.
Presence or absence of each sequence variant in DNA from each of
the individual larvae tested was recorded. The data were treated as
multi-locus binary data, in which each sequence variant was considered
to have two possible states (absent= 0, present= 1). One-wayanalysis
of variance (ANOVA) for the number of sequence variants per in-
dividual larva, by population, and subsequent Tukey pairwise com-
parisons and Kruskal-Wallis tests were conducted using Minitab17
statistical software.
Fig. 3. (continued)
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3. Results
3.1. Generation of full-length Tci-pgp-9 cDNA sequences
Full-length Tci-pgp-9 cDNAs (3.8 kb) were successfully ampliﬁed
from pools of L3 using primer pairs Tci-pgp-9_5′_F2 and Tci-pgp-9_R2 for
the MTci2 isolate and Tci-pgp-9_5′_F1 and Tci-pgp-9_R1 for the MTci5
isolate. Sequences were generated in both the sense and antisense di-
rections from each of three clones per isolate, and assembled to form
Table 1
Percentage identity of Tci-pgp-9-IBDA sequence variants.
The percentage identity between the Tci-pgp-9-IBDA sequence variants from the UK and NZ strains of T. circumcincta were calculated from the
number of base substitutions per site from between sequences. Analyses were conducted in MEGA7 (Kumar et al., 2016), using the Kimura 2-
parameter model (Kimura, 1980). Fewer than 5% alignment gaps, missing data and ambiguous bases were allowed at any position. The sequence
variants with the identity>95% (shaded) formed the basis for the numbered classiﬁcation of the corresponding UK sequence variants. Note that
UKv11-UKv14 had no corresponding NZ variant with> 90% identity.
Fig. 4. Phylogenetic Relationships of Tci-pgp-9-IBDA Sequence Variants
Molecular phylogenetic analyses were conducted using MEGA7 to select the best ﬁt
substitution model. The Maximum Likelihood method based on the Kimura 2-parameter
model was used to construct a bootstrap consensus tree inferred from 2000 replicates to
show the relationships between the sequence variants of Tci-pgp-9-IBDA, found in the UK
and NZ strains of T. circumcincta, respectively. A discrete Gamma distribution was used to
model evolutionary rate diﬀerences among sites (5 categories (+G, para-
meter = 0.6377)).
Fig. 5. Frequency of Tci-pgp-9-IBDA Sequence Variants in the MTci2 and MTci5 Isolates
Frequency of Tci-pgp-9-IBDA sequence variants identiﬁed from the MTci2 (white), MTci5
(grey) and MTci5PT (black) isolates of T. circumcincta. Note that column percentages for
each isolate add up to> 200% because many individual larva yielded multiple geno-
types.
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contiguous sequences for each UK ﬁeld isolate and comparisons of the
Tci-pgp-9 gene sequences from MTci2 and MTci5 conducted. Common
motifs shared by members of the ABC-transporter superfamily were
identiﬁed by comparing with ABC-transporter sequence motifs char-
acterised in Brugia malayi (Ardelli et al., 2010) and annotated in the
contiguous sequences (Fig. 1), thus verifying that the sequenced tran-
script was that of a P-glycoprotein.
At the nucleotide level, the full-length Tci-pgp-9 cDNAs from the
MTci2 and MTci5 isolates shared 95.6% identity (identical at 3651/
3822 bases) [Accession Numbers: MTci2 - LT724249 and MTci5 –
LT724250] while the amino acid sequences deduced from them shared
99.5% identity (1267/1273 residues). These sequences are likely to
represent two of several diﬀerent sequence variants of Tci-pgp-9 sub-
sequently found in these two isolates. In each case, those cloned were
assumed to be the most abundant of the Tci-pgp-9 variants present in the
isolate from which they were derived. Nine point-mutations not present
in the transcript derived from the MTci2 isolate were identiﬁed in that
derived from the MTci5 isolate, and these resulted in six residue
changes: V28E, A662T, T663A, A664T, R697S, and Q1131P, respec-
tively (Fig. 1). None of the non-synonymous SNPs that were identiﬁed
were located in any of the conserved sequence motifs. Of the 162 sy-
nonymous SNPs present, 12 were located in each of the sequence motifs
in the ﬁrst Tci-pgp-9-internucleotide binding domain (IBDA) and two
were found in the Walker A motif within the second Tci-pgp-9-inter-
nucleotide binding domain (IBDB). The remaining 148 were distributed
throughout the sequence.
Comparisons were made between amino acid sequences deduced
from the full-length Tci-pgp-9 cDNA clones from the UK isolates of T.
circumcincta and those deduced from the Tci-pgp-9 sequences from an-
thelmintic susceptible and multiple-resistant strains of NZ origin
(Bisset, 2007; and unpublished data, S. A. Bisset). The amino acid se-
quences of the susceptible UK ﬁeld-derived MTci2 and NZ inbred sus-
ceptible (NZ-S) strains shared 99.6% identity (identical at 1268/1273
residues) and the UK and NZ resistant (NZ-R) strains shared 99.9%
identity (identical at 1272/1273 residues). Clones derived from the
MTci2 and MTci5 isolates both displayed similar sequences to those
derived from the anthelmintic resistant strain from NZ at three of the
four non-synonymous SNPs at residues 79, 86 and 1097 (annotated A, B
and D, respectively, in Fig. 1). At the fourth non-synonymous SNP,
residue 1043 (annotated C in Fig. 1), the UK MTci2 and MTci5 isolates
shared the ‘susceptible genotype’ displayed in the NZ near-isogenic
strains. The four non-synonymous SNPs that were identiﬁed in the re-
sistant NZ strain but absent from the susceptible NZ strain were all
absent in the UK isolates of T. circumcincta.
3.2. Amplifying and sequencing Tci-pgp-9-IBDA variants
To identify genomic sequence variants of Tci-pgp-9-IBDA, a nested
PCR strategy and degenerate primers were used. PCR products gener-
ated varied in size, both within and between individuals (Fig. 2). A
panel of amplicons of varying size from individual larvae were selected
for sequencing and the data aligned with nine distinct sequence var-
iants from the NZ resistant and susceptible isolates. When classifying
sequence variants it was considered impractical to take into account
every apparent SNP. In most cases, groupings were based on blocks of
nucleotide substitutions, insertions or deletions within introns, which
were repeatedly associated with particular sequence variants (Fig. 3).
Eight of the ten Tci-pgp-9-IBDA sequence variants identiﬁed in NZ T.
circumcincta strains (Bisset, 2007) were also found in the UK strains.
These sequence variants aligned closely with NZ variants (NZv) sharing
95–100% identity (Table 1), and were annotated accordingly. Four
sequence variants identiﬁed in the UK strains were more divergent from
the known NZ sequence variants, and were assigned the numbers
11–14. A phylogenetic tree was constructed to show relationships
(Fig. 4) between the sequence variants found in UK and NZ strains of T.
circumcincta, supporting the high levels of identity observed within this
ampliﬁed gDNA fragment of Tci-pgp-9-IBDA. Sequence variants NZv1
and NZv4 were not observed in the UK strains, although UKv11 was
found to be most closely related to NZv1, sharing 89% identity. Se-
quence data for a sequence variant that most closely resembled the
NZv6 was generated from a single larva belonging to the MTci5 isolate.
However, it was not encountered again in larvae from these UK isolates,
suggesting it was relatively rare.
3.3. Sequence variant-speciﬁc genotyping
A series of sequence variant-speciﬁc primers were designed to dis-
tinguish between the Tci-pgp-9-IBDA sequence variant(s) present in in-
dividual larvae (Fig. 3). These primers targeted unique areas of poly-
morphism in each sequence variant (GenBank accession numbers listed
in Table S2), which in most cases ensured that they did not cross-react
with other sequence variants. However, as can be seen in Fig. 3, the
sequences generated from the sequence variant ‘UKv14’ of Tci-pgp-9-
IBDA possessed relatively few polymorphisms that were unique to this
variant, limiting the sites available for the placement of a sequence
variant-speciﬁc primer. As a result, the primers designed to identify the
presence of this variant, Tci-pgp-9_IBDARASV14A and Tci-pgp-9_IB-
DARASV14B, proved to be unsuitable due to problems with cross-re-
activity with other variants, therefore their use was discontinued. Using
Fig. 6. Number of Tci-pgp-9-IBDA Sequence Variants Identiﬁed in Individual Larvae
Larvae from the MTci2 (84), MTci5 (84) and MTci5PT (80) were screened for the pre-
sence of the 13 diﬀerent sequence variants. The number or sequence variants per in-
dividual was plotted and a Kruskal-Wallis test was conducted to compare the median
values: MTci2= 3, MTci5= 3 and MTci5PT=2 (p < 0.001).
Fig. 7. Frequency Distribution of Tci-pgp-9 Genotypes Over All Populations Combined
Diﬀerent combinations of sequence variants that occurred in the larvae were assigned a
“genotype”. The genotypes displayed by larvae from the 3 UK strains studied (MTci2,
MTi5 and MTci5PT) were combined to show that the majority of genotypes were unique
and seen in only a single larva, with just 5 genotypes being seen in 8 or more individual
larvae.
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sequence variant-speciﬁc PCR reactions, the presence or absence of
each sequence variant was determined in 84 individual larvae from
each of the MTci2 and MTci5 isolates and in 80 individual larvae from
the MTci5PT isolate. The frequencies of each of the sequence variants in
each of the isolates are shown in Fig. 5. As is clear from this ﬁgure,
column percentage totals in all cases exceed 200%, the total that might
be expected if every individual larva was heterozygous and generated
two distinct genotypes. The results thus suggest the involvement of
gene ampliﬁcation.
Frequently more than one sequence variant occurred in an in-
dividual larva, as indicated by more than one PCR product, for example
in lanes B1, B5 and B10 in Fig. 2. Indeed, the results of the sequence
variant-speciﬁc PCR revealed that up to ten diﬀerent Tci-pgp-9-IBDA
sequence variants occurred in some individual larvae belonging to the
MTci2 isolate, while individual larvae belonging to the MTci5 isolate
possessed up to 7 diﬀerent variants, and larvae from the MTci5PT
isolate possessed up to 5 diﬀerent variants (p < 0.001) (Fig. 6). The
one way-ANOVA method was used to compare the average number of
sequence variants in larvae from each isolate, and showed that MTci2
had a signiﬁcantly higher mean of 3.8 sequence variants, compared
with 2.7 in the MTci5 isolate and 2.2 in the MTci5PT isolate
(p < 0.001). A Tukey pairwise comparison between the isolates in-
dicated the MTci2 isolate was signiﬁcantly diﬀerent from the MTci5
and MTci5PT isolates.
The combination of sequence variants that each larva possessed was
allocated a genotype number (Table S3). A total of 124 diﬀerent gen-
otypes were identiﬁed across the three worm isolates. The majority of
these were unique in the sense that they occurred in just a single larva.
Only ﬁve of them occurred in 8 or more individuals (Fig. 7). Because
the Tci-pgp-9 copy number in individual larvae was not known it was
not possible to determine which of them carried multiple copies of any
particular sequence variant.
4. Discussion
Full-length (3.8 kb) cDNA transcripts of Tci-pgp-9 from anthelmintic
susceptible and multi-drug resistant UK isolates of T. circumcincta were
sequenced and compared to Tci-pgp-9 cDNA sequences derived from
two near-isogenic strains of T. circumcincta from NZ (Bisset, 2007; and
unpublished data, S. A. Bisset). Comparisons of the Tci-pgp-9 transcripts
ampliﬁed from MTci2 and MTci5 identiﬁed 171 polymorphic loci, of
which 9 nucleotide substitutions resulted in 6 amino acid substitutions.
Four substitutions at codons 662–664 and 697 were found to occur in
sequences from both the NZ and UK resistant isolates. Tci-pgp-9 se-
quences derived from the anthelmintic susceptible strains, MTci2 and
NZ-S, both displayed Ala-Thr-Ala at amino acids 662–664 and arginine
at amino acid 697, whilst those ampliﬁed from MTci5 resistant strain
displayed Thr-Ala-Thr the 662–664 residues and serine at amino acid
697. The signiﬁcance of these geographically distinct resistant isolates
sharing non-synonymous SNPs at these positions in Tci-pgp-9 remains to
be determined. We do not yet know whether similar polymorphisms in
Tci-pgp-9 are associated with resistance to IVM in other isolates of T.
circumcincta. Furthermore, these polymorphisms may not be isolate-
speciﬁc, but rather genotype-speciﬁc. For example, arginine and
threonine were found to be present at residues 79 and 86 in sequence
variant 1 which was the most common genotype in the NZ inbred
susceptible strain but was not in the other sequence variants; similarly
Ala-Thr-Ala and Arg at residues 662–664 and 697, respectively, were
only present in sequence variants 1 and 2 while Thr-Ala-Thr and Ser at
the same residues was seen in sequence variants 3, 6, 9 and 10 which
were most commonly found in the NZ multiple resistant strain (Bisset,
2007; and unpublished data, S. A. Bisset).
As a possible mechanism of resistance, the distribution of non-sy-
nonymous SNPs observed throughout the Tci-pgp-9 gene might inﬂu-
ence the tertiary structure of the gene, perhaps altering drug binding
(Gottesman and Pastan, 1993). Additionally, the synonymous SNPs may
cause changes in substrate speciﬁcity, possibly by changing the timing
of co-translational folding and thus the conformation of the Pgp mo-
lecule (Buss and Callaghan, 2008; Kimchi-Sarfaty et al., 2007). Changes
in the codon sequence, and therefore codon usage, have been linked to
the secondary structure of the proteins they encode. Some residues
show a higher probability of being buried in the centre of the protein
molecule and others are more likely to be exposed on the surfaces of the
folded protein (Saunders and Deane, 2010). Synonymous codons en-
coded by diﬀerent nucleotides are not used with equal frequency (Tao
and Dafu, 1998) resulting in the incorporation of “rarer” codons, the
availability of which may impede translation speed. Structural in-
formation that is linked to translation speed (Saunders and Deane,
2010), might inﬂuence translation rate and subsequently protein
folding (Kimchi-Sarfaty et al., 2007). Such changes could alter Pgp
tertiary structure and potentially substrate speciﬁcity and drug binding,
therefore, the inﬂuence of both synonymous and non-synonymous SNPs
on the rate of drug eﬄux warrants further investigation in multi-drug
resistant isolates of T. circumcincta.
Bisset (2007) reported the occurrence of alternative splicing that
resulted in a deletion of 45 residues in the N-terminal transmembrane
region of Tci-pgp-9 in multiple resistant T. circumcincta. An alternatively
spliced Pgp with a deletion of a similar size and location, has also been
reported to occur at a high level in two independently derived multi-
drug resistant Chinese hamster lung cell lines, while being absent in a
drug sensitive Chinese hamster lung cell line (Devine et al., 1991). As
only full-length Tci-pgp-9 cDNA PCR products were cloned and se-
quenced in the present study, we are unable to conﬁrm whether a si-
milar alternatively spliced Tci-pgp-9 gene occurs in these UK isolates of
T. circumcincta.
Considerable variation in the gDNA sequence of the N-terminal in-
ternucleotide binding domain, Tci-pgp-9-IBDA, was identiﬁed in in-
dividuals from UK isolates of T. circumcincta. The sequences generated
(Fig. 3) were compared with 9 sequence variants previously identiﬁed
in the same Tci-pgp-9-IBDA region isolated from NZ strains of T. cir-
cumcincta (Bisset, 2007). The sequence variants in over 80 randomly
selected larvae from each of MTci2, MTci5 and MTci5PT isolates of T.
circumcincta were classiﬁed into 12 distinct “sequence variants”. Eight
of the nine sequence variants seen in the NZ strains were also present in
the UK isolates, with NZv1 the only exception. The level of identity
shared between the UK and NZ Tci-pgp-9-IBDA sequence variants
(95–100%), suggests a high degree of conservation of these sequence
variants in these two geographically diverse T. circumcincta isolates.
Despite this however, the results showed a high degree of sequence
diversity in the introns, as well as numerous synonymous SNPs in the
exons of Tci-pgp-9-IBDA. It is conceivable that polymorphisms else-
where in the Tci-pgp-9 cDNA sequence may be linked to the sequence
variants identiﬁed in the intronic regions in the Tci-pgp-9-IBDA domain,
although this remains to be proven. The possibility of having an allele
that is capable of diminishing the toxic eﬀects of a drug is greater in
genetically diverse species, such as the trichostrongyloid nematodes, H.
contortus (Beech et al., 1994) and T. circumcincta (Blackhall et al.,
1998).
Based on the ampliﬁcation of sequence variant-speciﬁc PCR pro-
ducts from individual worms, comparisons of the observed frequency of
sequence variants were conducted. The majority (78.6%) of individuals
in the anthelmintic susceptible isolate, MTci2, carried between 1 and 4
sequence variants, while the remaining 21.4% carried>5 sequence
variants of Tci-pgp-9. The maximum number of sequence variants ob-
served in an individual MTci2 larva was 10, suggesting at least 5 het-
erozygous copies of the Tci-pgp-9 gene were ampliﬁed by the sequence
variant-speciﬁc PCR. Possessing up to ten diﬀerent variants may pro-
vide some individuals with a panel of Tci-pgp-9 sequence variants which
potentially oﬀers a ﬁtness advantage over other individuals. A reduc-
tion in the number of sequence variants in individuals of the anthel-
mintic resistant isolate (MTci5) was observed, with 92.9% of in-
dividuals carrying≤ 4 variants and the remaining 7.1% of larvae
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possessing 5–7 sequence variants. The MTci5 population was not de-
rived from MTci2 so we cannot deﬁnitively ascribe changes in popu-
lation structure to selection, however, the results are in line with the
possibility that purifying selection might have eliminated sequence
variants that were not advantageous under exposure to anthelmintics.
The MTci5 isolate exhibits a resistance phenotype to BZs and LEV, thus
diﬀerences in genotype between MTci2 and MTci5 might also be due to
selection with anthelmintics other than IVM. The further reduction in
the number of sequence variants observed in the MTci5PT isolate
(which had survived in vivo exposure to IVM), provides support for this
possibility as 79 of the 80 larvae from this population which were
genotyped displayed≤ 4 variants with just one individual possessing 5
sequence variants.
In summary, the present study revealed 1) 4 non-synonymous nu-
cleotide substitutions (residues 662–664 and 697) in Tci-pgp-9 sequence
variants shared by the multiple-resistant UK and NZ isolates but which
were not observed in their drug-susceptible counterparts; 2) that mul-
tiple sequence variants of Tci-pgp-9 were present in the majority of in-
dividuals, consistent with previous evidence that ampliﬁcation of this
gene has occurred in T. circumcincta; 3) that there was a reduction in the
diversity of Tci-pgp-9 sequence variants in individuals of the anthel-
mintic resistant MTci5 isolate relative to those in the anthelmintic
susceptible MTci2 isolate and a further reduction in the number of
diﬀerent variants present in individuals derived from an IVM treated
population of MTci5, suggesting that IVM treatment had applied pur-
ifying selection pressure.
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